Table 3 The incremental cost-effectiveness results of the exploratory scenarios from the private and patient’s perspective and time horizon of 5 years
Histopathology + Stratictye™ | Histopathology | |
|---|---|---|
(A) Scenario #1 | ||
Total cost | $3,192 | $3,550.69 |
Total cancer cases | 0.28 (28 per 100 patient | 0.35 (35 per 100 patient) |
Incremental cost | ($ 359) | Histopathology + Stratictye™ DOMINATES Histopathology |
Cancer cases avoided | 0.07 | |
ICER | Dominates (cost saving) | |
(B) Scenario #2 | ||
Total cost | $2,605 | $1,399.45 |
Total cancer cases | 0.24 (24 per 100 patient) | 0.38 (38 per 100 patient) |
Incremental cost | ($ 1205) | |
Cancer cases avoided | 0.14 | |
ICER | $8,610/ cancer case avoided | |